Astrana Health, Inc.

OVERVALUEDASTH · NASDAQ · Healthcare
ASTH·NASDAQ·Healthcare
OVERVALUED
Astrana Health, Inc.
33.2%downside
MARKET PRICE
$34.13
FAIR PRICE
$22.79
MARGIN
$11.34
UNDERVALUEDFAIROVERVALUED
P/E RATIO
N/A
DIV. YIELD
N/A
ROE
1.3%
MARKET CAP
$2B
FPI
fairpriceindex.com

FAIR PRICE VALUATION

33.2%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$34.13

FAIR PRICE

$22.79

MARGIN

$11.34

UNDERVALUEDFAIROVERVALUED

P/E Ratio

N/A

Div. Yield

N/A

ROE

1.3%

Average

Market Cap

$2B

Small-cap

NOW AVAILABLE

Get notified when ASTH's fair price changes

Push notifications when ASTH's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

3.6/ 10

Consistent growth trajectory, but below-average fundamental quality and elevated debt levels.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$18.23CONSERVATIVE ENTRY
$22.79FAIR PRICE
$34.13MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$18.23

Fair price × 0.80

DISTANCE

46.6%

Price to entry level

At the current price of $34.13, ASTH trades 46.6% above the conservative entry level of $18.23. This entry level represents a 20% margin of safety below the calculated fair price of $22.79 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

Loading chart data...

P/E RATIO HISTORY

Loading chart data...

METHODOLOGY

How we calculate ASTH's fair price

Astrana Health, Inc.'s fair price of $22.79 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $34.13, ASTH trades 33.2% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ASTH's risk profile.

RELATIVE · 30%

Comparing ASTH's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for ASTH, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate ASTH's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for ASTH.

Explore on Bulios

FAQ

What is the fair price of ASTH?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Astrana Health, Inc. is $22.79. At the current market price of $34.13, ASTH trades 33.2% above its calculated fair value.

Is ASTH overvalued or undervalued?+

Astrana Health, Inc. is currently overvalued based on our valuation model. The stock trades at $34.13, which is 33.2% above the fair price of $22.79.

What is the margin of safety for ASTH?+

With a 20% margin of safety applied to the fair price of $22.79, the conservative entry level for ASTH is $18.23. At the current market price of $34.13, the stock trades 46.6% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is ASTH's fair price updated?+

We update fair price calculations for ASTH daily after market close. The current fair price of $22.79 incorporates the latest market data and sector multiples.

What factors affect ASTH's fair price calculation?+

ASTH's fair price of $22.79 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 1.3%.

Is ASTH a good buy right now?+

At $34.13, ASTH trades 33.2% above our fair value estimate of $22.79. The stock is currently overvalued. ROE stands at 1.3% (average). Fair Price Index provides valuation data — always do your own research before investing.

Does ASTH pay dividends?+

ASTH does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.